En respuesta a BTiJQYGoDfvzaVGHi
 |  Publicar respuesta

Have you read any good books lately? http://tubereviews.online madthumbs In the study, 69% of patients receiving alirocumab experienced side effects, compared to 78% of patients receiving ezetimibe. The most side effects were infections--including influenza and upper respiratory tract infection--which occurred in 42% of patients receiving Regeneron and Sanofi's drug, compared to 39% in the control arm.

Añadir comentario